ASSET PURCHASE AND LICENSE AMENDMENT AGREEMENTAsset Purchase and License Amendment Agreement • December 27th, 2022 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 27th, 2022 Company Industry JurisdictionThis Asset Purchase and License Amendment Agreement (this “Agreement”), dated as of December 27, 2022 (the “Agreement Date”), is entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Seller”), and Gilead Sciences, Inc., a Delaware corporation (“Buyer,” and with Seller, individually, each a “Party” and, collectively, the “Parties”). Any capitalized term not defined herein that is defined in the License Agreement (as defined below) shall have the meaning set forth in the License Agreement.